Literature DB >> 18776825

Invasive pneumococcal disease among human immunodeficiency virus-infected children, 1989-2006.

Andrew P Steenhoff1, Sarah M Wood, Richard M Rutstein, Allison Wahl, Karin L McGowan, Samir S Shah.   

Abstract

OBJECTIVE: The heptavalent pneumococcal conjugate vaccine (PCV7) has decreased the incidence of pediatric invasive pneumococcal disease (IPD) in the United States. Few data exist on the changing IPD incidence in HIV-infected children.
METHODS: Diagnostic codes and clinical microbiology laboratory records identified cases of IPD from 1989 to 2006 in perinatally-infected children <18 years of age followed at an urban HIV clinic. IPD incidence was calculated and serotype distribution and antibiotic resistance were recorded.
RESULTS: Two-hundred fifty-six patients were followed for 1756 person-years (PY). The sample was 59% female, 76% black, 14% white, and 8% Hispanic. Of 21 episodes of IPD (1200/100,000 PY), 17 (81%) were female. IPD cases had a median age of 6.3 years (interquartile range [IQR]: 2.3-9.9 years), median CD4% of 17% (IQR: 11-28%), and median CD4 count of 415 cells/mm (range, 2-1699 cells/mm). Bacteremia was the commonest form of IPD (19 episodes; 1080/100,000 PY). After HAART introduction in 1996, the incidence of IPD decreased 84% from 1862/100,000 PY in 1989-1995 to 292/100,000 PY in 1997-1999 (incidence rate ratio [IRR]: 0.16, P = 0.03). After PCV7 introduction in 2000, IPD incidence showed a nonsignificant increase from 292 of 100,000 PY in 1997-1999 to 860 of 100,000 PY in 2001-2006 (IRR: 2.94; P = 0.16). The percentages of IPD isolates nonsusceptible to penicillin and trimethoprim-sulfamethoxazole were 19% and 33%, respectively. Vaccine serotypes accounted for 38% of isolates, vaccine-related 14%, nonvaccine 33%, and the serotype was unknown in 14%.
CONCLUSIONS: The incidence of IPD among perinatally HIV-infected children decreased after the introduction of HAART. Ongoing monitoring is required to determine the effect of PCV7 on IPD in this vulnerable population.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18776825     DOI: 10.1097/INF.0b013e3181734f8f

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  6 in total

1.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

2.  Delayed reconstitution of B cell immunity to pneumococcus in HIV-infected Malawian children on antiretroviral therapy.

Authors:  Oluwadamilola H Iwajomo; Peter Moons; Rose Nkhata; David Mzinza; Abiodun D Ogunniyi; Neil A Williams; Robert S Heyderman; Adam Finn
Journal:  J Infect       Date:  2014-11-01       Impact factor: 6.072

3.  Pregnancy intervals after stillbirth, neonatal death and spontaneous abortion and the risk of an adverse outcome in the next pregnancy in rural Bangladesh.

Authors:  Bareng A S Nonyane; Maureen Norton; Nazma Begum; Rasheduzzaman M Shah; Dipak K Mitra; Gary L Darmstadt; Abdullah H Baqui
Journal:  BMC Pregnancy Childbirth       Date:  2019-02-09       Impact factor: 3.007

4.  Effectiveness of pneumococcal conjugate vaccination against invasive pneumococcal disease among children with and those without HIV infection: a systematic review and meta-analysis.

Authors:  Hossein Molavi Vardanjani; Hodjat Borna; Ali Ahmadi
Journal:  BMC Infect Dis       Date:  2019-08-05       Impact factor: 3.090

Review 5.  The burden of invasive pneumococcal disease in children with underlying risk factors in North America and Europe.

Authors:  M A Rose; D Christopoulou; T T H Myint; I de Schutter
Journal:  Int J Clin Pract       Date:  2013-07-19       Impact factor: 2.503

Review 6.  Role of Inflammatory Risk Factors in the Pathogenesis of Streptococcus pneumoniae.

Authors:  Ifrah Sohail; Sumit Ghosh; Santhosh Mukundan; Susan Zelewski; M Nadeem Khan
Journal:  Front Immunol       Date:  2018-10-02       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.